Secarna Pharmaceuticals GmbH & Co. KG | WebDisclosure

Basculer en Français

9804	Companies
196632	Keywords
127649	Articles
104544	Press releases

Headlines Articles Press releases Secarna Pharmaceuticals GmbH & Co. KG

Home
Companies
Secarna Pharmaceuticals GmbH & Co. KG

PRESS RELEASE

published on 03/26/2025 at 14:00, 10 months 9 days ago

Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 as monotherapy and in combination with immune checkpoint inhibitors at AACR
Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 at AACR, showcasing potential to enhance immune checkpoint inhibitors' efficacy

Secarna Pharmaceuticals AACR Antisense Oligonucleotide SECN-15 NRP1
BRIEF

published on 10/31/2024 at 16:08, 1 year 3 months ago

Secarna Pharmaceuticals nomme son nouveau PDG, Konstantin Petropoulos

Nomination Du PDG Produits Biopharmaceutiques Secarna Pharmaceutique Constantin Petropoulos Thérapeutique Par Oligonucléotides
BRIEF

published on 10/31/2024 at 16:08, 1 year 3 months ago

Secarna Pharmaceuticals Appoints New CEO Konstantin Petropoulos

CEO Appointment Biopharmaceuticals Secarna Pharmaceuticals Konstantin Petropoulos Oligonucleotide Therapeutics
PRESS RELEASE

published on 10/31/2024 at 16:03, 1 year 3 months ago

Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Office
Secarna Pharmaceuticals announces Konstantin Petropoulos as new CEO, succeeding Alexander Gebauer, focusing on oligonucleotide therapeutics. Petropoulos brings extensive industry experience

Business Development CEO Appointment Secarna Pharmaceuticals Konstantin Petropoulos Oligonucleotide Therapeutics
BRIEF

published on 09/09/2024 at 14:05, 1 year 4 months ago

Secarna Pharmaceuticals présentera le potentiel de l'ASO lors du sommet sur les thérapies contre les inflammasomes

Secarna Pharmaceutique Inflammation NLRP3 Les OSA Sommet Sur Les Thérapies À Base D'inflammasome
BRIEF

published on 09/09/2024 at 14:05, 1 year 4 months ago

Secarna Pharmaceuticals to Showcase ASO Potential at Inflammasome Therapeutics Summit

Secarna Pharmaceuticals ASOs Inflammation NLRP3 Inflammasome Therapeutics Summit
PRESS RELEASE

published on 09/09/2024 at 14:00, 1 year 4 months ago

Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3
Secarna Pharmaceuticals presents ASO data targeting NLRP3 at Inflammasome Therapeutics Summit, showcasing potential in inflammatory disease treatment

Secarna Pharmaceuticals ASOs NLRP3 Inflammasome Summit Inflammatory Disease
BRIEF

published on 09/04/2024 at 14:05, 1 year 5 months ago

Secarna crée un comité consultatif en oncologie composé des experts Prof. Dr. Eggermont et Prof. Dr. Zippelius

Secarna Pharmaceutique Conseil Consultatif Scientifique SECN-15 Experts En Oncologie Neuropiline 1
BRIEF

published on 09/04/2024 at 14:05, 1 year 5 months ago

Secarna Establishes Oncology Advisory Board with Experts Prof. Dr. Eggermont and Prof. Dr. Zippelius

Scientific Advisory Board Secarna Pharmaceuticals Oncology Experts SECN-15 Neuropilin 1
PRESS RELEASE

published on 09/04/2024 at 14:00, 1 year 5 months ago

Secarna establishes Scientific Advisory Board with leading oncology experts Prof. Dr. Eggermont and Prof. Dr. Zippelius
Secarna Pharmaceuticals GmbH & Co. KG establishes an oncology Scientific Advisory Board with leading experts Prof. Dr. Eggermont and Prof. Dr. Zippelius to guide the development of SECN-15 and the oncology pipeline

Scientific Advisory Board Oncology Therapeutics Secarna Pharmaceuticals SECN-15

Accesswire

Published on 02/04/2026 at 18:00, 3 hours 31 minutes ago

Lithium South AGSM Update
Published on 02/04/2026 at 16:15, 5 hours 16 minutes ago

Trans Canada Gold Enters into an Option Agreement with Bear Mountain Gold Mines to Acquire a 60% Interest in the Harrison Lake District Scale Gold Property, with $10.0 Million Dollars in Prior Exploration Expenditures
Published on 02/04/2026 at 15:45, 5 hours 46 minutes ago

Patriot.Tv's Jd Rucker Explains Billie Eilish's Comments on ICE, Offers ICE Commentary as Exhibit A of Celebrity Sound Bite Politics
Published on 02/04/2026 at 15:00, 6 hours 31 minutes ago

Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale
Published on 02/04/2026 at 14:30, 7 hours 1 minute ago

Datametrex Expands Business In Data Centres

View all ACCESSWIRE

EQS Group

Published on 02/04/2026 at 20:54, 36 minutes ago

Elmos Semiconductor SE is planning to distribute 36 million Euro to shareholders for the fiscal year 2025
Published on 02/04/2026 at 20:36, 54 minutes ago

EQS-Adhoc: Elmos Semiconductor SE approves share buyback program via the stock exchange of 10 million Euro and dividend proposal of 1.50 Euro per share for fiscal year 2025
Published on 02/04/2026 at 20:00, 1 hour 30 minutes ago

Belgium's Ingmar De Vos elected to Executive Board of International Olympic Committee
Published on 02/04/2026 at 18:55, 2 hours 35 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/04/2026 at 18:40, 2 hours 50 minutes ago

Robin Zeng: Unlocking the Sustainable Energy Era with Zero-Carbon Technology

Les Echos

Published on 02/04/2026 at 18:04, 3 hours 26 minutes ago

Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 3 hours 26 minutes ago

Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 3 hours 46 minutes ago

Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 3 hours 46 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 02/04/2026 at 17:45, 3 hours 46 minutes ago

Janvier 2026

View all LES ECHOS COMFI WIRE